Sofinnova Investments’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Sofinnova Investments’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-410,000	Closed	-$2.46M	–	66
2022 Q4	$2.46M	Buy	+410,000	New	+$2.24M	0.15%	46

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Sofinnova Investments's CTIC Position: Q2 2023 in Review

Sofinnova Investments sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 2,794,542 shares — an estimated $11.7M sold.

Sofinnova Investments first reported a position in CTIC in Q2 2021 and held it in 7 quarters. The position peaked at $27.7M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Sofinnova Investments reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Sofinnova Investments sold 2,794,542 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $11.7M.
Sofinnova Investments first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2021 and held it in 7 quarters.
Sofinnova Investments's CTI BioPharma Corp. (DE) Common Stock position peaked at $27.7M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Sofinnova Investments's 13F filing for Q2 2023, filed 14 Aug 2023.